ELI LILLY & Co（LLY）の決算・業績分析
ELI LILLY & Coの2025年有価証券報告書をAI分析。売上高$65.2B(+44.7%)。Health Care。
目次
ELI LILLY & Coの2025年度 業績サマリー
ELI LILLY & Co（証券コード: LLY）の2025年度決算・業績分析。売上高は$65.2B（前年比+44.7%）。純利益は$20.6B（前年比+94.9%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
ELI LILLY & Coの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- LLY achieved $28.5B revenue in FY2024 (+0.8% YoY) and $6.2B net income (+11.9% YoY) (XBRL).
- ROE reached 58.0% with $2.8B cash reserves and $15.5B net debt (1.6x EBITDA) (XBRL).
- Free cash flow totaled $3.8B, with $5.0B returned to shareholders via dividends and buybacks (XBRL).
ELI LILLY & Coの売上高変化の要因
- •FY2024 revenue of $28.5B grew 0.8% YoY, driven by Mounjaro, Zepbound, and Verzenio, partially offset by Trulicity (10-K). Historical revenue growth accelerated to +9.7% CAGR over 5 years, with FY2024 revenue surpassing FY2023’s $28.3B (XBRL). No segment-specific revenue data is available (N/A).
ELI LILLY & Coの営業利益変化の要因
- •Operating income rose to $8.3B (29.0% margin) and net income to $6.2B (21.9% margin), up 11.9% YoY (XBRL). Higher gross margin improved profitability, but increased R&D, SG&A, and administrative expenses pressured results (10-K). EBITDA reached $9.8B (34.4% margin), reflecting strong operational efficiency (XBRL).
ELI LILLY & Coの事業リスクと対応
High R&D costs and drug development uncertainty, with many failures and limited commercial success (10-K).
Regulatory delays and approval hurdles across markets, risking product launches and revenue (10-K).
Inability to replace revenue from products losing IP protection or facing competition (10-K).
Challenges in business development, including integration risks and regulatory scrutiny of acquisitions (10-K).
Dependence on key products and failure to replenish the pipeline, threatening long-term growth (10-K).
ELI LILLY & Coの今後の見通し・業績予想
ELI LILLY & Coの事業内容
Eli Lilly & Co (LLY) operates as a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing prescription drugs (10-K). Key therapeutic areas include Cardiometabolic Health (e.g., Jardiance, Mounjaro, Trulicity) and Oncology (e.g., Cyramza, Retevmo), targeting chronic conditions like diabetes, obesity, and cancer through collaborations (10-K). The company competes via innovation in drug development and R&D pipeline advancements, though specific competitors are not named in the 10-K. No employee data or geographic revenue breakdowns are provided (N/A).
ELI LILLY & CoのAI業績分析レポート（2024年度）
Eli Lilly & Co (LLY) FY2024 Annual Report Analysis
Highlights
Business Overview
Eli Lilly & Co operates in the pharmaceutical sector, focusing on prescription drugs for chronic conditions like diabetes, obesity, and cancer. Key products include Mounjaro, Trulicity, and Cyramza, with therapeutic areas spanning cardiometabolic health and oncology. The company leverages R&D innovation and collaborations but faces risks from high development costs and regulatory hurdles (10-K). No employee or geographic data is disclosed (N/A).
Revenue Analysis
FY2024 revenue of $28.5B grew 0.8% YoY, driven by Mounjaro, Zepbound, and Verzenio, partially offset by Trulicity (10-K). Historical growth averaged +9.7% CAGR over 5 years, with FY2024 revenue surpassing FY2023’s $28.3B (XBRL). Segment-specific revenue data is unavailable (N/A).
Profitability Analysis
Operating income rose to $8.3B (29.0% margin) and net income to $6.2B (21.9% margin), up 11.9% YoY (XBRL). Higher gross margin improved profitability, but increased R&D, SG&A, and administrative expenses pressured results (10-K). EBITDA reached $9.8B (34.4% margin) (XBRL).
Balance Sheet Analysis
Total assets grew to $64.0B in FY2024, with equity at $10.8B (16.8% equity ratio) (XBRL). Long-term debt rose to $18.3B, resulting in $15.5B net debt (1.6x EBITDA). Cash reserves stood at $2.8B, but current ratio was 0.94x (XBRL). No geographic or segment asset breakdowns are available (N/A).
Cash Flow Analysis
Operating cash flow totaled $7.6B, exceeding net income of $6.2B (XBRL). Free cash flow was $3.8B, with $3.5B in dividends and $1.5B in share repurchases returned to shareholders (XBRL). Investing cash flow was -$3.8B, and financing cash flow was -$5.4B (XBRL). No CapEx or acquisition details are provided (N/A).
Working Capital Analysis
Cash conversion cycle (CCC) was 291 days, driven by 116-day receivables, 318-day inventory, and 143-day payables (XBRL).
Risks
Outlook
Management expects growth from Mounjaro, Zepbound, and Verzenio, along with clinical pipeline advancements (10-K). Increased R&D expenses are anticipated to support innovation and offset revenue loss from IP-expired drugs (10-K). No explicit forward-looking guidance is provided (N/A).
Health Careの企業一覧
ELI LILLY & Coと同じ「Health Care」セクターの企業